What is a potential consequence of administering enoxaparin?

Administering enoxaparin, a low molecular weight heparin used primarily for anticoagulation, can lead to an increased risk of thrombocytopenia, which is a reduction in the number of platelets in the blood. This condition occurs as a hypersensitivity reaction in some patients, resulting in either heparin-induced thrombocytopenia (HIT) or a more generalized reduction in platelet count. Monitoring platelet levels is essential during treatment with enoxaparin to identify this side effect early, especially since thrombocytopenia can increase the risk of bleeding complications.

In contrast, while the other options may present potential concerns in different contexts, they are not associated with enoxaparin administration in the same way. For instance, enoxaparin does not typically lead to the development of hypertension or metabolic syndrome, nor does it have a direct effect on potassium levels. Therefore, the increased risk of thrombocytopenia is a significant and relevant consequence of enoxaparin therapy that requires attention in clinical management.